denkapparat Operations GmbH Buys 160 Shares of Insulet Corporation $PODD

denkapparat Operations GmbH boosted its position in shares of Insulet Corporation (NASDAQ:PODD) by 16.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,118 shares of the medical instruments supplier’s stock after acquiring an additional 160 shares during the period. denkapparat Operations GmbH’s holdings in Insulet were worth $351,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Inspire Investing LLC boosted its stake in Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 3,088 shares in the last quarter. Gradient Investments LLC acquired a new stake in shares of Insulet during the 2nd quarter valued at about $17,429,000. Goldman Sachs Group Inc. boosted its position in shares of Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after acquiring an additional 10,628 shares in the last quarter. Vident Advisory LLC bought a new stake in Insulet in the first quarter valued at about $216,000. Finally, Mn Services Vermogensbeheer B.V. raised its position in Insulet by 7.5% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 27,300 shares of the medical instruments supplier’s stock worth $8,577,000 after purchasing an additional 1,900 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PODD shares. UBS Group lifted their price objective on Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Canaccord Genuity Group boosted their price target on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Piper Sandler lifted their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Royal Bank Of Canada upped their target price on shares of Insulet from $365.00 to $370.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insider Transactions at Insulet

In related news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company’s stock.

Insulet Price Performance

Insulet stock opened at $336.84 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The firm has a market cap of $23.70 billion, a P/E ratio of 102.38, a P/E/G ratio of 2.64 and a beta of 1.39. The business’s fifty day moving average is $324.17 and its two-hundred day moving average is $311.37. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same period last year, the company posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.